**INTRODUCTION:** Although mesh reinforcement has improved clinical outcomes in ventral hernia repair (VHR), notable disadvantages have arisen with both synthetic and biologic meshes such as increased infection rates and increased cost, respectively, with variable recurrence rates. Long-term resorbable mesh presents an encouraging option for complex VHR, designed to leverage the benefits and improve the deficiencies of synthetic and biologic mesh. This study aims to assess the clinical outcomes and quality of life (QoL) of patients undergoing poly-4-hydroxybutyrate (P4HB) mesh reinforcement for complex VHR.

**METHODS:** A retrospective review was conducted of all consecutive VHR with P4HB mesh reinforcement from October 2015 to January 2018 by a single surgeon. Patient demographics, operative outcomes, and QoL were evaluated. Pre and postoperative QoL was assessed using the HerQLes questionnaire. Descriptive statistics and linear regression analyses were performed.

**RESULTS:** Seventy patients (n = 70) undergoing VHR with P4HB mesh were included. Average age and body mass index were 59.4 years (23.2--81.4) and 33 kg/m^2^, respectively. High-risk comorbidities included diabetes mellitus (23%), obesity (59%), hypertension (59%), and history of smoking (50%). Ninety-five percent of patients underwent \>1 previous abdominal surgery, in which 36% (n = 25) presented with a recurrent hernia. Average defect size was 323 cm^2^ (25--972 cm^2^), where cases were primarily clean (64%) or clean-contaminated (26%), and modified Ventral Hernia Working Group class II (n = 35; 50%) or III (n = 25; 36%). P4HB was primarily placed in the retromuscular plane (80%), followed by an onlay (20%) and fixated with either suture (n = 51; 73%) or fibrin glue (n = 19; 27%). Over a mean follow-up of 24 months (range, 12.2--41 months), the hernia recurrence rate was 4% (n = 4). Hernia recurrence occurred an average of 285 days (range, 209--368 days) post-P4HB repair. Average length of stay was 5 days (0--38). Postoperative complications consisted of superficial delayed wound healing (n = 12; 19%), seroma (n = 6; 9%), and cellulitis (n = 4; 6%). Of the 22 surgical site occurrences, only 5 (7%) required surgical intervention. Multivariate analysis identified a significant trend for surgical site occurrences in nonclean cases (*P* = 0.023). There were no instances of mesh infection or explantation. Comparisons in pre- and postoperative QoL (n = 59; 84%) identified a significant improvement in overall QoL (*P* = 0.001) and at each follow-up window (*P* \< 0.005). No significant differences were identified in postoperative QoL, regardless of complication or hernia recurrence.

**CONCLUSIONS:** P4HB reinforcement for complex VHR is associated with favorable long-term clinical outcomes, acceptable complication rates, including hernia recurrence, and a significant improvement in QoL. This study further supports the benefits of biosynthetic mesh to serve as a viable construct for VHR in a complex patient population.
